TriSalus Life Sciences, Inc.

NASDAQ:TLSI

Medical - Devices

Healthcare
$2.45 +0.49%

+$0.02 today

Market cap
$151.16M
Beta
0.49
P/E (TTM)
-7.4
EPS (TTM)
-$0.53
52W Low $2.20High $7.95

Volume 0.40M

Average 0.38M

TLSI Free Cash Flow

Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.

TriSalus Life Sciences, Inc.NASDAQ: TLSI

Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Free cash flow growth accelerates

Q1 FY2026 free cash flow of $6.62M (cash outflow) rose 26.0% year over year, ahead of the -42.8% change in trailing-twelve-month free cash flow. Sequentially, it rose 162.2% from the prior quarter. Over 3 fiscal years it compounded at -17.0% a year.

Context

  • Free cash flow amounted to 41.9% of revenue in FY2025, down 98.0 pp from a year earlier.
  • Free cash flow grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +26.0% holds above the trailing-twelve-month pace of -42.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$6.62M+162.2% QoQ
Last fiscal yearDec 2025
-$18.93M-54.0% YoY
LTMMar 2026
-$20.3M-42.8% YoY
Free Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+26.0%——
1 year-54.0%——
3-year CAGR-17.0%——
5-year CAGR——
10-year CAGR——

Free Cash Flow history

USD · from the cash flow

Latest · FY2025
(18.93M) USD
Year-over-year change
+54.0%

Free Cash Flow vs competitors

How TLSI compares with its peers on the latest reported figures

  • TLSI's LTM Mar 2026 free cash flow of $20.3M is the 8th largest of the 11 companies compared; the peer median is $31.82M.
  • Its year-over-year change of -42.8% is the 9th highest of 10, against a peer median of +3.5%.
  • Free cash flow amounts to 45.2% of revenue for TLSI, versus a peer median of 149.0%.
TLSI Competitors Peer median
Free Cash Flow for TLSI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CATXPerspective Therapeutics, Inc.LTM Mar 2026$107.32M +3.5%+96.9%17365.9%
AVRAnteris Technologies Global Corp.LTM Mar 2026$86.69M +25.6%+36.9%4683.3%
NNOXNano-X Imaging Ltd.LTM Dec 2025$47.63M +21.0%-3.8%365.8%
PROFProfound Medical Corp.LTM Mar 2026$38.97M +44.5%+14.8%206.5%
PREPrenetics Global LimitedLTM Mar 2026$34.14M ——30.0%
MXCTMaxCyte, Inc.LTM Mar 2026$29.51M -10.5%+2.8%91.4%
ARMPArmata Pharmaceuticals, Inc.LTM Mar 2026$24.47M -32.5%-8.8%827.3%
TLSITriSalus Life Sciences, Inc.LTM Mar 2026$20.3M -42.8%-17.0%45.2%
STIMNeuronetics, Inc.LTM Mar 2026$13.58M -63.6%-14.6%9.0%
LNSRLENSAR, Inc.LTM Mar 2026$12.24M +202.4%-0.1%21.2%
OWLTOwlet, Inc.LTM Mar 2026$11.16M -23.6%-48.9%10.4%
Peer median (excluding TLSI) $31.82M+3.5%-0.1%149.0%

Competitors are the stored peer set for TLSI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(28.85M)(47.19M)(59.36M)(30.05M)(39.23M)
Depreciation & Amortization464K398K684K744K626K
Deferred Income Tax00000
Stock-Based Compensation109K368K1.4M5.44M9.13M
Change in Working Capital(131K)2.3M537K(9.55M)2.07M
Accounts Receivables(741K)(200K)(1.98M)(1.72M)(1.63M)
Inventory(725K)(179K)(1.07M)(1.5M)971K
Accounts Payables3.18M5.25M2.84M(4.38M)2.02M
Other Working Capital(1.84M)(2.57M)751K(1.94M)711K
Other Non-Cash Items5.71M11.81M6.16M(7.43M)9.39M
Operating Cash Flow(22.7M)(32.31M)(50.58M)(40.84M)(18.01M)
Capital Expenditures(1.26M)(786K)(588K)(345K)(918K)
Acquisitions (Net)000080K
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities(1.16M)(1.13M)(1M)00
Investing Cash Flow(2.26M)(1.79M)(1.59M)(345K)(838K)
Debt Repayment(1.3M)(131K)(87K)24.92M9.92M
Common Stock Issued00015.54M22.91M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities54K94K45.53M(2.52M)(2.07M)
Financing Cash Flow50.77M13.46M54.63M37.94M30.76M
Effect of Forex Changes00000
Net Change in Cash25.81M(20.64M)2.46M(3.25M)11.91M
Free Cash Flow(23.96M)(33.1M)(51.17M)(41.19M)(18.93M)

TriSalus Life Sciences, Inc.

NASDAQ:TLSI

Intrinsic Alpha fair value

Locked

Current Price

$2.45

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.